A New ELISA for Dermatomyositis Autoantibodies: Rapid Introduction of Autoantigen cDNA to Recombinant Assays for Autoantibody Measurement

Table 1

Comparison of clinical data for patients with anti-Mi-2 antibody in a previous report and in the present study.

	Multicenter study*	This study
Anti-Mi-2 (+) pts., number (%)	9/376 (2.4)	7/124 (5.6)
Age at onset, median (range), y	45 (16–66)	62 (40–73)
Sex, M/F, number	6/3	1/6
Diagnosis, %
Classical DM	100	100
Clinically amyopathic DM	0	0
Clinical features, %
Muscle weakness	100	100
Arthritis	11	14
ILD	11	0
Malignancy	0	0
Skin eruptions, %
Heliotrope rash	67	57
Facial erythema**	56	100
Gottron sign	89	100
Prognosis (alive), %	100	100

∗Data from [10]. This cohort includes 7 patients used in this study, all of whom were negative for anti-Mi-2 antibodies. **Facial erythema other than heliotrope rash.